Corcept Therapeutics IncorporatedCORTNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P10
Near historical low
vs 3Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -5.80% |
| Q3 2025 | 13.85% |
| Q2 2025 | -0.43% |
| Q1 2025 | -13.61% |
| Q4 2024 | 18.48% |
| Q3 2024 | 1.01% |
| Q2 2024 | 0.41% |
| Q1 2024 | 6.94% |
| Q4 2023 | 20.19% |
| Q3 2023 | 5.18% |
| Q2 2023 | 5.94% |
| Q1 2023 | 11.15% |
| Q4 2022 | 10.40% |
| Q3 2022 | 1.42% |
| Q2 2022 | 16.73% |
| Q1 2022 | -1.40% |
| Q4 2021 | 1.52% |
| Q3 2021 | -0.50% |
| Q2 2021 | -2.72% |
| Q1 2021 | 2.64% |
| Q4 2020 | -16.52% |
| Q3 2020 | 27.82% |
| Q2 2020 | 1.43% |
| Q1 2020 | 7.45% |
| Q4 2019 | 6.61% |
| Q3 2019 | 5.31% |
| Q2 2019 | 6.97% |
| Q1 2019 | 7.72% |
| Q4 2018 | -0.35% |
| Q3 2018 | -8.19% |
| Q2 2018 | 20.49% |
| Q1 2018 | 25.07% |
| Q4 2017 | 16.58% |
| Q3 2017 | 48.46% |
| Q2 2017 | 9.75% |
| Q1 2017 | 10.67% |
| Q4 2016 | -8.08% |
| Q3 2016 | 24.37% |
| Q2 2016 | 22.40% |
| Q1 2016 | 13.33% |